



CNRT and IBA sign collaboration agreement to install a Cyclone® IKON in China

The Cyclone® IKON is IBA's new high energy and high-capacity cyclotron which offers the largest energy spectrum for PET and SPECT isotopes from 13 MeV to 30 MeV

Louvain-La-Neuve, Belgium, August 30, 2022 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world's leading provider of radiopharmaceutical production solutions, announced it has signed a collaboration agreement with Chengdu New Radiomedicine Technology Co., Ltd (CNRT) to install a Cyclone® IKON in Chengdu, Sichuan Province, China. CNRT is a Chinese manufacturer and provider of medical isotopes used for oncology diagnosis and therapy. The typical end-user price for a Cyclone® IKON solution is between EUR 15 and 20 million.

The Cyclone® IKON will be used for the production of novel isotopes for use in theranostics and targeted therapies, particularly for Germanium-68 (used for Germanium-68/Gallium-68 generators), Iodine-123 and other radioisotopes such as Copper-64. These enable the administration of radiation directly to the targeted cells, with minimal toxic side effects to surrounding healthy cells, unlike traditional modalities.

Jiming Cai, General Manager of CNRT, commented: *“We are pleased to be working with IBA to develop a stable and independent supply of commonly used medical isotopes. This will be the first Cyclone® IKON cyclotron system to be installed by IBA in China for the production of multiple radioisotopes, and is expected to be fully operational by 2025. In due course CNRT will be able to provide high-quality and efficient medical isotopes to our clients.”*

Bruno Scutnaire, President of IBA RadioPharma Solutions, added: *“There are a growing number of clinical trials and an increase in new radiotherapeutic molecule developments, with many companies recognizing the great potential of theranostics. Since its launch in 2020, this is the fourth Cyclone® IKON unit sold globally and we look forward to working with CNRT over the coming months and years.”*

About CNRT

Chengdu New Radiomedicine Technology Co., Ltd. was established in the year 2016. It is a high-tech enterprise integrating Research and development of radiopharmaceuticals, innovation and industrialization, engaged in research, production and sales of medical isotopes, carry out demonstration research on the diagnosis and treatment of a variety of malignant tumor diseases, provide nuclear medicine technical services and scientific and technological consulting, etc. The company has built up an advanced radiopharmaceutical testing and research platform, an advanced radioactive pharmacology research platform, and an advanced radiopharmaceutical industrialization innovation platform. CNRT will ensure continuously provide high-quality, High efficiency and affordable radioactive diagnosis and treatment drugs for the patients, provide high-quality medical



isotope nuclide products for the radiopharmaceutical industry, through technology, concept and products innovation.

About IBA

IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA is also a leading player in the fields of industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 1,600 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.

IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

More information can be found at: www.iba-worldwide.com

CONTACTS

Soumya Chandramouli

Chief Financial Officer

+32 10 475 890

Investorrelations@iba-group.com

Olivier Lechien

Corporate Communication Director

+32 10 475 890

communication@iba-group.com

Consilium Strategic Communications

Amber Fennell, Angela Gray, Lucy Featherstone

+44 (0) 20 3709 5700

IBA@consilium-comms.com